How Companion Diagnostics Can Support Targeted Drug Launches

• by Jane Li

• September 29, 2026

Bridging the PSMA PET/CT access gap in prostate cancer: evidence, barriers, and priorities for implementation

• by J. Gómez Rivas, L. Fernández Hernández, L. Turpin, A. Peyrottes, M. Rouprêt

• September 29, 2026

Hodgkin lymphoma transformation in patients with chemotherapy-naïve chronic lymphocytic leukemia

• by Paul J. Hampel, Ying Huang, John N. Allan, Seema A. Bhat, David Bond, Danielle M. Brander, John C. Byrd, Julio C. Chavez, Elise Chong, Alexey Danilov, Matthew S. Davids, Kaitlyn Dvorak-Kornaus, Hannah Freedman, Nikita Malakhov, Matthew Matasar, Cecelia Miller, Sarah Miller, Zulfa Omer, Sameer A. Parikh, Erin M. Parry, Kari G. Rabe, Phil Raess, Manoj Rai, Joanna M. Rhodes, Kerry A. Rogers, Aditi Saha, Jake Schade, Geoffrey Shouse, Stephen Spurgeon, Deborah Stephens, Yucai Wang, Jennifer A. Woyach, Max Yano, Adam S. Kittai

• September 26, 2026

MAPK Inhibitors Restore CAR T-Cell Target in Thyroid Cancer Models

Trametinib and dabrafenib increased TSHR expression and improved the activity of CAR T cells in a patient-derived model of anaplastic thyroid cancer

• September 24, 2026

• 3 min